Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $828,247 | 405 | 82.2% |
| Travel and Lodging | $112,490 | 450 | 11.2% |
| Consulting Fee | $34,017 | 20 | 3.4% |
| Food and Beverage | $32,238 | 899 | 3.2% |
| Education | $26.32 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $926,994 | 1,169 | $0 (2024) |
| Mylan Specialty L.P. | $71,072 | 151 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,478 | 40 | $0 (2024) |
| GlaxoSmithKline, LLC. | $815.30 | 65 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $570.71 | 38 | $0 (2023) |
| Grifols USA, LLC | $551.80 | 16 | $0 (2022) |
| Gilead Sciences, Inc. | $441.57 | 19 | $0 (2021) |
| ABBVIE INC. | $344.58 | 17 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $305.38 | 16 | $0 (2024) |
| Philips Electronics North America Corporation | $275.96 | 19 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $171,259 | 227 | AstraZeneca Pharmaceuticals LP ($167,904) |
| 2023 | $170,119 | 252 | AstraZeneca Pharmaceuticals LP ($163,562) |
| 2022 | $183,638 | 262 | AstraZeneca Pharmaceuticals LP ($172,608) |
| 2021 | $168,741 | 289 | AstraZeneca Pharmaceuticals LP ($163,434) |
| 2020 | $23,902 | 88 | AstraZeneca Pharmaceuticals LP ($14,178) |
| 2019 | $62,864 | 189 | Mylan Specialty L.P. ($40,168) |
| 2018 | $94,630 | 216 | AstraZeneca Pharmaceuticals LP ($93,646) |
| 2017 | $131,865 | 255 | AstraZeneca Pharmaceuticals LP ($130,098) |
All Payment Transactions
1,778 individual payment records from CMS Open Payments — Page 2 of 72
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Respiratory | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $925.00 | General |
| Category: Respiratory | ||||||
| 08/28/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $925.00 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $283.41 | General |
| Category: Respiratory | ||||||
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $132.10 | General |
| Category: Respiratory | ||||||
| 08/16/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $96.15 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $219.72 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $219.72 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $217.00 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $167.50 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $122.24 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $113.87 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $55.69 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $49.98 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $46.17 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $45.36 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $39.92 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: Respiratory | ||||||
| 07/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: Respiratory | ||||||
| 07/25/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $618.96 | General |
| Category: Respiratory | ||||||
| 07/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $534.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/04/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $125.00 | General |
| Category: Respiratory | ||||||
| 06/28/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $26.54 | General |
| Category: VIROLOGY | ||||||
| 06/26/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 976 | 1,304 | $207,234 | $108,932 |
| 2022 | 7 | 883 | 1,238 | $203,989 | $103,984 |
| 2021 | 11 | 1,140 | 1,532 | $235,130 | $128,916 |
| 2020 | 13 | 1,329 | 1,803 | $216,724 | $144,367 |
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 288 | 579 | $144,750 | $75,194 | 51.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 87 | 87 | $20,010 | $14,001 | 70.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 83 | 92 | $16,100 | $8,318 | 51.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 200 | 203 | $17,255 | $5,819 | 33.7% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 11 | 11 | $3,300 | $3,107 | 94.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 45 | 45 | $2,250 | $884.94 | 39.3% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 25 | 46 | $1,150 | $657.80 | 57.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 22 | 23 | $1,035 | $587.75 | 56.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 14 | 14 | $364.00 | $356.72 | 98.0% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2023 | 201 | 204 | $1,020 | $5.17 | 0.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 294 | 604 | $151,000 | $77,724 | 51.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 67 | 67 | $15,410 | $9,965 | 64.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 88 | 103 | $17,479 | $9,229 | 52.8% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 178 | 184 | $15,640 | $5,383 | 34.4% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2022 | 44 | 44 | $2,200 | $869.82 | 39.5% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2022 | 34 | 54 | $1,350 | $807.45 | 59.8% |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | Office | 2022 | 178 | 182 | $910.00 | $6.12 | 0.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 301 | 604 | $148,655 | $80,042 | 53.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 189 | 239 | $37,912 | $21,783 | 57.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 94 | 94 | $21,620 | $15,119 | 69.9% |
| 94060 | Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration | Office | 2021 | 215 | 222 | $18,870 | $7,730 | 41.0% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 19 | 19 | $1,520 | $1,262 | 83.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 17 | $1,974 | $1,111 | 56.3% |
| 99406 | Smoking and tobacco use intermediate counseling, greater than 3 minutes up to 10 minutes | Office | 2021 | 37 | 64 | $1,600 | $962.64 | 60.2% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 27 | 27 | $1,350 | $581.77 | 43.1% |
About Dr. George Parides, DO
Dr. George Parides, DO is a Pulmonary Disease healthcare provider based in Mesa, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851379879.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. George Parides, DO has received a total of $1.0M in payments from pharmaceutical and medical device companies, with $171,259 received in 2024. These payments were reported across 1,778 transactions from 65 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($828,247).
As a Medicare-enrolled provider, Parides has provided services to 4,328 Medicare beneficiaries, totaling 5,877 services with total Medicare billing of $486,199. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Critical Care Medicine
- Location Mesa, AZ
- Active Since 01/09/2006
- Last Updated 04/01/2015
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1851379879
Products in Payments
- BREZTRI (Drug) $537,712
- BEVESPI AEROSPHERE (Drug) $189,906
- AIRSUPRA (Drug) $92,978
- Yupelri (Drug) $64,065
- SYMBICORT (Drug) $43,208
- FASENRA (Biological) $26,586
- BREZTRI AEROSPHERE (Drug) $14,175
- DALIRESP (Drug) $7,419
- YUPELRI (Drug) $7,007
- XIFAXAN (Drug) $449.58
- TRELEGY ELLIPTA (Drug) $422.07
- FASENRA (Drug) $370.35
- Prolastin-C Liquid (Biological) $345.70
- FARXIGA (Drug) $325.86
- DUPIXENT (Biological) $322.27
- STIOLTO RESPIMAT (Drug) $239.96
- STELARA (Biological) $221.99
- Prolastin-C (Biological) $206.10
- IBSRELA (Drug) $198.21
- TYVASO (Drug) $191.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Mesa
Dr. Steven Farber, Do, DO
Pulmonary Disease — Payments: $21,369
Dr. Robert Groves, M.d, M.D
Pulmonary Disease — Payments: $4,541
G Sulit, Md, MD
Pulmonary Disease — Payments: $4,060
Alhassan Badahman, M.d, M.D
Pulmonary Disease — Payments: $3,937
Dashant Kavathia, Md, MD
Pulmonary Disease — Payments: $3,271
Seyed Javadpoor, Md, MD
Pulmonary Disease — Payments: $3,044